Drugs / Varilrix
Varilrix
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT00568334 | Nov 2007 → Mar 2008 | chickenpox | GlaxoSmithKline | Completed | Met primary |
| Phase 2 | NCT00353288 | Mar → Nov 2006 | measles, mumps infectious disease, rubella, varicella zoster infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00492739 | Jun 2007 → Apr 2022 | chickenpox, liver disorder | University Hospital, Geneva | Unknown | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT00226499 | Sep 2005 → Oct 2006 | chickenpox | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00406211 | Jul → Dec 2004 | chickenpox, measles, mumps infectious disease, rubella | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02383797 | Feb 2015 → Oct 2019 | cartilage-hair hypoplasia | Helsinki University Central Hospital | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01765413 | Sep 2013 → Jan 2014 | — | University of Surrey | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT05130398 Comparator | Apr → Sep 2021 | Ebola hemorrhagic fever | Centre de Recherche Médicale de Lambaréné | Completed | No outcome recorded |
| Phase 3 | NCT02570126 Comparator | Nov 2015 → Oct 2016 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT02173704 Comparator | Sep 2014 → Dec 2015 | meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT01439360 Comparator | Oct 2011 → Oct 2014 | influenza | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00969436 Comparator | Nov 2009 → Feb 2011 | measles, mumps infectious disease, rubella, varicella zoster infection | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00624819 Background | Mar → Jun 2008 | pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VARILRIX | “Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.” NCT02173704 ↗12“Measles-mumps-rubella Vaccine (Priorix™) Co-administered With Varicella Vaccine (Varilrix™)” NCT00353288 ↗ “Participants receive one dose of 'Varilrix' varicella-zoster vaccine.” NCT01765413 ↗ “Varilrix” NCT00492739 ↗ |
| Known as | Varicella | “Varicella (Varilrix®)” NCT00406211 ↗ |
| Known as | Varicella Vaccine | “Varicella Vaccine (Varilrix™)” NCT00353288 ↗ |
| Modality | Vaccine | “live attenuated varicella vaccine” NCT00226499 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT00226499 ↗ |